Drug intelligence / Profile preview

Amoxicillin + Levofloxacin + Omeprazole + Tinidazole

Development stage
Unknown
Lead developer
RedHill Biopharma
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination therapy specifically mentioned for the eradication of **Helicobacter pylori (H. pylori)** infection. It consists of three antibiotics (amoxicillin, levofloxacin, and tinidazole) and a proton pump inhibitor (omeprazole). **Amoxicillin** is a beta-lactam antibiotic that works by inhibiting bacterial cell wall synthesis. **Levofloxacin** is a fluoroquinolone antibiotic that inhibits bacterial DNA topoisomerase II, effective against various bacteria including H. pylori. **Omeprazole** is a proton pump inhibitor that reduces stomach acid production. **Tinidazole** is a nitroimidazole antibiotic, similar to metronidazole. This combination is typically used in a **sequential therapy** regimen for H. pylori. One described regimen involves administering omeprazole and amoxicillin for the first 5 days, followed by omeprazole, levofloxacin, and tinidazole for the next 5 days. Studies mentioned in the search results indicate high eradication rates with this approach, potentially higher than clarithromycin-containing sequential therapies.

02

Targets

PBP (Penicillin-binding protein family)Topo IV (Bacterial Topoisomerase IV)DNADNA gyraseATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Amoxicillin + Levofloxacin + Omeprazole + Tinidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amoxicillin + Levofloxacin + Omeprazole + Tinidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call